Lisata Therapeutics, Inc.
LSTA
Rank in Stocks
#28695
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on... Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues. The company's product portfolio features several notable candidates: HONEDRA, which has received SAKIGAKE designation and is presently in Phase II clinical trials for critical limb ischemia; XOWNA, currently undergoing Phase IIb testing for coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy aimed at individuals with chronic kidney disease who are not yet on dialysis. Founded in 1980 and based in Basking Ridge, New Jersey, the company was initially known as NeoStem, Inc., then rebranded as Caladrius Biosciences, Inc. in June 2015, before assuming its present identity as Lisata Therapeutics, Inc. on September 15, 2022.
Share Price
$1.12
Last synced: 2026-11-09
Market Cap
$10.09M
Change (1 day)
8.74%
Change (1 year)
-48.15%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Lisata Therapeutics, Inc. (LSTA)
Category
Healthcare
EPS for Lisata Therapeutics, Inc. (LSTA)
EPS as of June 2026 TTM: $-1.64
According to Lisata Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-1.64. At the end of 2025 the company had an EPS of $-1.91, an increase over its 2024 EPS of $-2.40.
EPS history for Lisata Therapeutics, Inc. from 2000 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.64 | -14.14% |
| 2025 | $-1.91 | -20.42% |
| 2024 | $-2.40 | -6.98% |
| 2023 | $-2.58 | -75.36% |
| 2022 | $-10.47 | 40.54% |
| 2021 | $-7.45 | -5.82% |
| 2020 | $-7.91 | -72.91% |
| 2019 | $-29.20 | 16.66% |
| 2018 | $-25.03 | -165.13% |
| 2017 | $38.43 | -151.37% |
| 2016 | $-74.81 | -70.09% |
| 2015 | $-250.12 | -0.46% |
| 2014 | $-251.28 | -11.92% |
| 2013 | $-285.29 | -52.45% |
| 2012 | $-600.00 | -25.93% |
| 2011 | $-810.00 | 19.63% |
| 2010 | $-677.08 | -81.50% |
| 2009 | $-3.66K | 59.48% |
| 2008 | $-2.30K | -51.89% |
| 2007 | $-4.77K | 9.17% |
| 2006 | $-4.37K | 17.68% |
| 2005 | $-3.71K | -42.03% |
| 2004 | $-6.40K | 2.65% |
| 2003 | $-6.24K | -23.01% |
| 2002 | $-8.10K | -42.36% |
| 2001 | $-14.06K | 0.26% |
| 2000 | $-14.02K | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -1,054.88% |
US
|
|
| $-7.07 | 331.10% |
US
|
|
| $-5.29 | 222.56% |
AU
|
|
| $12.88 | -885.37% |
BE
|
|
| $21.56 | -1,414.63% |
NL
|
Questions about Lisata Therapeutics, Inc.'s earnings per share (EPS)
What is Lisata Therapeutics, Inc.'s earnings per share (EPS)?
Lisata Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-1.64, as of Jun 2026.
What was Lisata Therapeutics, Inc.'s earnings per share (EPS) in 2025?
In 2025, Lisata Therapeutics, Inc.'s earnings per share (EPS) was $-1.91, compared with $-2.40 in 2024.
How has Lisata Therapeutics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Lisata Therapeutics, Inc.'s earnings per share (EPS) was highest in 2025 ($-1.91) and lowest in 2022 ($-10.47).
How does Lisata Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
Lisata Therapeutics, Inc.'s earnings per share (EPS) ($-1.64) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.